InvestorsHub Logo
Followers 43
Posts 5432
Boards Moderated 0
Alias Born 11/15/2013

Re: None

Sunday, 02/01/2015 3:04:36 PM

Sunday, February 01, 2015 3:04:36 PM

Post# of 403061
I noticed the writer of the linked article's primary interests is novel small molecule drugs, next generation vaccines, and cell therapies.

My Comment the following:
"Cellceutix has a robust pipeline of 3 drugs including the cancer drug Kevetrin currently in phase1 cohort10 at Dana Farber Cancer center with some positive results against ovarian cancer. Also a defensin mimetic antibiotic called Brilacidin having finished a very positive phase2b outcome comparing Cubicin 7 day dose regimine against Brilacidin 1 day dose for ABSSSI infection. Brilacidin preparing to start phase3 soon. Also a drug by the name of Prurisol for combating psoriasis. Prurisol is a small molecule that acts through immune modulation and has been seen to have incredible invitro results in clearing psoriasis in mouse models. Prurisol phase2 is set to begin any day"

http://www.fool.com/investing/general/2015/02/01/an-8-billion-hedge-fund-bought-this-extremely-risk.aspx#commentsBoxAnchor
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News